Teva Pharmaceutical Industries (TEVA) Goodwill & Intangibles (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Goodwill & Intangibles for 18 consecutive years, with $19.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Goodwill & Intangibles fell 4.01% year-over-year to $19.3 billion; the trailing twelve-month figure through Jun 2026 stood at $19.3 billion (down 4.01% YoY), and the FY2025 full-year result was $19.8 billion, down 3.12% from the prior year.
• Goodwill & Intangibles slipped to $19.3 billion in Q2 2026 per TEVA's latest filing, from $19.4 billion in the prior quarter.
• Across five years, Goodwill & Intangibles topped out at $27.1 billion in Q1 2022 and bottomed at $19.3 billion in Q2 2026.
• Historically, Goodwill & Intangibles has averaged $22.0 billion across 5 years, with a median of $21.7 billion in 2024.
• The sharpest annual moves came in 2023 and 2026: Goodwill & Intangibles decreased 12.32% in 2023, then retreated 1.19% in 2026.
• Over 5 years, Goodwill & Intangibles stood at $23.4 billion in 2022, then slipped by 3.77% to $22.6 billion in 2023, then declined by 9.51% to $20.4 billion in 2024, then decreased by 3.12% to $19.8 billion in 2025, then retreated by 2.5% to $19.3 billion in 2026.
• According to Business Quant data, Goodwill & Intangibles over the past three periods registered $19.3 billion, $19.4 billion, and $19.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.